---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028987"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:48:50.575921+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cumberland Q3 revenue up 41% to $11.4M; net loss narrows to $0.4M

## Summary
- Net revenue $11.4M vs $8.1M a year ago, driven by Sancuso ($4.0M) and Kristalose ($3.9M).
- Net loss improved to $0.4M from $1.1M; adjusted earnings $1.4M ($0.10/share).
- Year-to-date cash from operations $5.6M, up 28% from $4.4M.
- Completed Sancuso transition under co-promotion with Verity; RediTrex amendment allows Nordic to assume U.S. commercialization after March 2023.
- Phase II ifetroban trials ongoing; AERD study closed to enrollment awaiting top-line results.

## SEC filing metadata
- accession: 0001628280-22-028987
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/cpix-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028987
- JSON: https://secwatch.observer/filing/0001628280-22-028987.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028987.txt

## Key facts
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported the three months ended September 30, 2022 results: revenue $11.4 million, net income Net loss for the third quarter of 2022 was $0.4 million.
  - Period: the three months ended September 30, 2022
  - Revenue: $11.4 million
  - Net income: Net loss for the third quarter of 2022 was $0.4 million
  - Result: reported results
  source text: Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm
- Earnings Releases
  CUMBERLAND PHARMACEUTICALS INC reported the nine months ended September 30, 2022 results: revenue $33 million.
  - Period: the nine months ended September 30, 2022
  - Revenue: $33 million
  - Result: reported results
  source text: of 2022, included $4.0 million for Sancuso ® , $3.9 million for Kristalose ® , $1.9 million for Vibativ ® and $0.9 million for Caldolor ® . Year-to-date 2022 net revenues were $33 million, a 19% increase compared to $28 million for the first nine months of 2021. Year-to-date net revenues by product were $11.4 million for Kristalose, $10.8 million for Sancuso, $6.0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.